Go Deep
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -20,575 | -18.4 | -5.07 | -0.88 | 6,320.24 |
| Oct 2026 | -20,595 | -18.5 | -5.11 | -0.89 | 6,294.94 |
| Oct 2026 | -22,602 | -17.8 | -4.92 | -0.89 | 6,028.29 |
| Oct 2026 | -22,754 | -18.2 | -5.05 | -0.89 | 6,165.89 |
| Oct 2026 | -22,956 | -18.3 | -5.22 | -0.89 | 6,374.73 |
| Oct 2026 | -22,888 | -18.6 | -5.16 | -0.89 | 6,288.13 |
| Oct 2026 | -23,032 | -19.1 | -5.28 | -0.89 | 6,441.83 |
| Oct 2026 | -22,996 | -19.0 | -5.25 | -0.89 | 6,404.85 |
| Oct 2026 | -23,013 | -19.0 | -5.26 | -0.89 | 6,407.00 |
| Oct 2026 | -23,049 | -19.1 | -5.29 | -0.89 | 6,429.90 |
| Oct 2026 | -23,089 | -19.3 | -5.33 | -0.89 | 6,498.27 |
BridgeBio Pharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 243,676,000.0 | 194,515,000.0 | 154,178,000.0 | 120,700,000.0 |
| Net Profit | -152,216,000.0 | -164,043,000.0 | -192,863,000.0 | -182,743,000.0 |
| EPS | -0.8 | -0.8 | -1.0 | -0.9 |
BridgeBio Pharma, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 502,076,000.0 | 221,902,000.0 | 9,303,000.0 | 77,648,000.0 | — |
| Net Profit | -724,931,000.0 | -535,762,000.0 | -643,202,000.0 | -481,183,000.0 | — |
| EPS | -3.8 | -2.9 | -4.0 | -3.3 | — |
BridgeBio Pharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 936,025,000.0 | 919,338,000.0 | 546,380,000.0 | 623,036,000.0 | — |
| Total Liabilities | 3,012,606,000.0 | 2,376,950,000.0 | 1,888,915,000.0 | 1,867,960,000.0 | — |
| Total Equity | -2,086,610,000.0 | -1,467,904,000.0 | -1,354,257,000.0 | -1,254,617,000.0 | — |
Owes vs Owns
BridgeBio Pharma, Inc. owed $3.06 for every $1 it owned in Jun 2026, up from $3.00 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 3.06× | 3.22× | 2.59× | 3.46× | 3.00× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
BridgeBio Pharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 62.8%Receivables 14.9%Inventory 2.9%Fixed assets (tangible) 1.4%Intangible assets 3.0%Long-term investments 8.5%Other assets 6.5%
How it's funded — Dec 2025
Long-term debt 61.5%Payables 1.2%Other liabilities 37.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 587.5 | 681.1 | 434.9 | 471.9 |
| Receivables | 139.4 | 4.7 | 1.8 | 17.1 |
| Inventory | 26.8 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 13.5 | 12.8 | 19.8 | 25.2 |
| Intangible assets | 28.1 | 23.9 | 26.3 | 28.7 |
| Long-term investments | 80.0 | 143.7 | 0.0 | 0.0 |
| Other assets | 60.8 | 53.1 | 63.6 | 80.1 |
| Liabilities & equity | ||||
| Short-term debt | 6.2 | 4.5 | 4.1 | 3.7 |
| Long-term debt | 1,852.5 | 1,721.4 | 1,726.7 | 1,707.6 |
| Payables | 36.2 | 9.6 | 10.7 | 11.6 |
| Other liabilities | 1,117.7 | 641.4 | 147.4 | 145.1 |
| Shareholders' equity | -2,076.6 | -1,457.6 | -1,342.5 | -1,244.9 |
| Net tangible assets | -2,114.7 | -1,491.8 | -1,380.6 | -1,283.3 |
BridgeBio Pharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -445,910,000.0 | -520,726,000.0 | -527,720,000.0 | -419,494,000.0 | — |
| Investing Activities | -24,487,000.0 | 60,781,000.0 | 54,033,000.0 | 453,147,000.0 | — |
| Financing Activities | 359,293,000.0 | 748,457,000.0 | 451,535,000.0 | -13,134,000.0 | — |